Drug intelligence / Profile preview

Benglouting granules (Shuyang Chenggui Hospital)

Development stage: Unknown
Lead developer: Shuyang Chenggui Hospital
Administration: Oral

Overview

Benglouting granules is a Traditional Chinese Medicine (TCM) formulation developed by Shuyang Chenggui Hospital for the treatment of abnormal uterine bleeding (AUB), specifically menorrhagia. In TCM theory, it is indicated for patients exhibiting the 'blood stasis' pattern. The product is administered orally as granules. It has been evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial in China to assess its efficacy and safety in reducing excessive menstrual blood loss and managing symptoms of flooding and leaking.

Brand names: Benglouting granules
Other names: Benglouting keliBeng Lou Ting

Beyond the preview

Go deeper on Benglouting granules (Shuyang Chenggui Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benglouting granules (Shuyang Chenggui Hospital).

Explore the full profile